AEG1 Cancer Research Results

AEG1, Astrocyte Elevated Gene-1: Click to Expand ⟱
Source:
Type:
AEG-1 (Astrocyte Elevated Gene-1), also known as Metadherin (MTDH) or LYRIC, is an oncogene that has garnered considerable attention due to its multifaceted roles in tumor progression, metastasis, and chemoresistance.
AEG-1 is involved in several cellular processes including proliferation, migration, invasion, angiogenesis, and epithelial-to-mesenchymal transition (EMT).
It influences multiple signaling pathways such as PI3K/AKT, NF-κB, and Wnt/β-catenin, which are critical for promoting survival, proliferation, and metastatic potential.
AEG-1’s ability to interact with various proteins and pathways makes it a central hub in fostering a supportive environment for tumor growth and progression.

AEG-1 is overexpressed in a wide range of cancers including breast, prostate, liver (hepatocellular carcinoma), glioblastoma, melanoma, and colorectal cancers, among others.
High expression levels are frequently detected in advanced tumor stages and often correlate with aggressive tumor phenotypes.


Scientific Papers found: Click to Expand⟱
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, As an antioxidant, Luteolin and its glycosides can scavenge free radicals caused by oxidative damage and chelate metal ions
*IronCh↑,
*toxicity↓, The safety profile of Luteolin has been proven by its non-toxic side effects, as the oral median lethal dose (LD50) was found to be higher than 2500 and 5000 mg/kg in mice and rats, respectively, equal to approximately 219.8−793.7 mg/kg in humans
*BioAv↓, One major problem related to the use of flavonoids for therapeutic purposes is their low bioavailability.
*BioAv↑, Resveratrol, which functions as the inhibitor of UGT1A1 and UGT1A9, significantly improved the bioavailability of Luteolin by decreasing the major glucuronidation metabolite in rats
DNAdam↑, Luteolin’s anticancer properties, which involve DNA damage, regulation of redox, and protein kinases in inhibiting cancer cell proliferation
TumCP↓,
DR5↑, Luteolin was discovered to promote apoptosis of different cancer cells by increasing Death receptors, p53, JNK, Bax, Cleaved Caspase-3/-8-/-9, and PARP expressions
P53↑,
JNK↑,
BAX↑,
cl‑Casp3↑,
cl‑Casp8↑,
cl‑Casp9↑,
cl‑PARP↑,
survivin↓, downregulating proteins involved in cell cycle progression, including Survivin, Cyclin D1, Cyclin B, and CDC2, and upregulating p21
cycD1/CCND1↓,
CycB/CCNB1↓,
CDC2↓,
P21↑,
angioG↓, suppress angiogenesis in cancer cells by inhibiting the expression of some angiogenic factors, such as MMP-2, AEG-1, VEGF, and VEGFR2
MMP2↓,
AEG1↓,
VEGF↓,
VEGFR2↓,
MMP9↓, inhibit metastasis by inhibiting several proteins that function in metastasis, such as MMP-2/-9, CXCR4, PI3K/Akt, ERK1/2
CXCR4↓,
PI3K↓,
Akt↓,
ERK↓,
TumAuto↑, can promote the conversion of LC3B I to LC3B II and upregulate Beclin1 expression, thereby causing autophagy
LC3B-II↑,
EMT↓, Luteolin was identified to suppress the epithelial to mesenchymal transition by upregulating E-cadherin and downregulating N-cadherin and Wnt3 expressions.
E-cadherin↑,
N-cadherin↓,
Wnt↓,
ROS↑, DNA damage that is induced by reactive oxygen species (ROS),
NICD↓, Luteolin can block the Notch intracellular domain (NICD) that is created by the activation of the Not
p‑GSK‐3β↓, Luteolin can inhibit the phosphorylation of the GSK3β induced by Wnt, resulting in the prevention of GSK3β inhibition
iNOS↓, Luteolin in colon cancer and the complications associated with it, particularly the decreasing effect on the expressions of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2)
COX2↓,
NRF2↑, Luteolin has been identified to increase the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), which is a crucial transcription factor with anticarcinogenic properties related
Ca+2↑, caused loss of the mitochondrial membrane action potential, enhanced levels of mitochondrial calcium (Ca2+),
ChemoSen↑, Luteolin enhanced the effect of one of the most effective chemotherapy drugs, cisplatin, on CRC cells
ChemoSen↓, high dose of Luteolin application negatively affected the oxaliplatin-based chemotherapy in a p53-dependent manner [52]. They suggested that the flavonoids with Nrf2-activating ability might interfere with the chemotherapeutic efficacy of anticancer
IFN-γ↓, decreased the expression of interferon-gamma-(IFN-γ)
RadioS↑, suggested that Luteolin can act as a radiosensitizer, promoting apoptosis by inducing p38/ROS/caspase cascade
MDM2↓, Luteolin treatment was associated with increased p53 and p21 and decreased MDM4 expressions both in vitro and in vivo.
NOTCH1↓, Luteolin suppressed the growth of lung cancer cells, metastasis, and Notch-1 signaling pathway
AR↓, downregulating the androgen receptor (AR) expression
TIMP1↑, Luteolin inhibits the migration of U251MG and U87MG human glioblastoma cell lines by downregulating MMP-2 and MMP-9 and upregulating the tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2.
TIMP2↑,
ER Stress↑, Luteolin caused oxidative stress and ER stress in the Hep3B cells,
CDK2↓, Luteolin’s ability to decrease Akt, polo-like kinase 1 (PLK1), cyclin B1, cyclin A, CDC2, cyclin-dependent kinase 2 (CDK2) and Bcl-xL
Telomerase↓, Luteolin dose-dependently inhibited the telomerase levels and caused the phosphorylation of NF-κB and the target gene of NF-κB, c-Myc to suppress the human telomerase reverse transcriptase (hTERT)
p‑NF-kB↑,
p‑cMyc↑,
hTERT/TERT↓,
RAS↓, Luteolin was found to suppress the expressions of K-Ras, H-Ras, and N-Ras, which are the activators of PI3K
YAP/TEAD↓, Luteolin caused significant inhibition of yes-associated protein (YAP)/transcriptional co-activator with PDZ-binding motif (TAZ)
TAZ↓,
NF-kB↓, Luteolin was found to have a strong inhibitory effect on the NF-κB
NRF2↓, Luteolin-loaded nanoparticles resulted in a significant reduction in the Nrf2 levels compared to Luteolin alone.
HO-1↓, The expressions of the downstream genes of Nrf2, Ho1, and MDR1 were also reduced, where inhibition of Nrf2 expression significantly increased the cell death of breast cancer cells
MDR1↓,

1139- UA,    Ursolic acid inhibits epithelial-mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells
- in-vitro, Lung, A549
TumMeta↓,
AEG1↓,
E-cadherin↑,
N-cadherin↓,
Vim↓,
EMT↓,


Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

HO-1↓, 1,   NRF2↓, 1,   NRF2↑, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics

CDC2↓, 1,  

Core Metabolism/Glycolysis

p‑cMyc↑, 1,  

Cell Death

Akt↓, 1,   BAX↑, 1,   cl‑Casp3↑, 1,   cl‑Casp8↑, 1,   cl‑Casp9↑, 1,   DR5↑, 1,   hTERT/TERT↓, 1,   iNOS↓, 1,   JNK↑, 1,   MDM2↓, 1,   NICD↓, 1,   survivin↓, 1,   Telomerase↓, 1,   YAP/TEAD↓, 1,  

Protein Folding & ER Stress

ER Stress↑, 1,  

Autophagy & Lysosomes

LC3B-II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair

DNAdam↑, 1,   P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence

CDK2↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   P21↑, 1,  

Proliferation, Differentiation & Cell State

EMT↓, 2,   ERK↓, 1,   p‑GSK‐3β↓, 1,   NOTCH1↓, 1,   PI3K↓, 1,   RAS↓, 1,   TAZ↓, 1,   Wnt↓, 1,  

Migration

AEG1↓, 2,   Ca+2↑, 1,   E-cadherin↑, 2,   MMP2↓, 1,   MMP9↓, 1,   N-cadherin↓, 2,   TIMP1↑, 1,   TIMP2↑, 1,   TumCP↓, 1,   TumMeta↓, 1,   Vim↓, 1,  

Angiogenesis & Vasculature

angioG↓, 1,   VEGF↓, 1,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling

COX2↓, 1,   CXCR4↓, 1,   IFN-γ↓, 1,   NF-kB↓, 1,   p‑NF-kB↑, 1,  

Hormonal & Nuclear Receptors

AR↓, 1,  

Drug Metabolism & Resistance

ChemoSen↓, 1,   ChemoSen↑, 1,   MDR1↓, 1,   RadioS↑, 1,  

Clinical Biomarkers

AR↓, 1,   hTERT/TERT↓, 1,  
Total Targets: 64

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 1,  

Metal & Cofactor Biology

IronCh↑, 1,  

Drug Metabolism & Resistance

BioAv↓, 1,   BioAv↑, 1,  

Functional Outcomes

toxicity↓, 1,  
Total Targets: 5

Scientific Paper Hit Count for: AEG1, Astrocyte Elevated Gene-1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1015  State#:%  Dir#:1
wNotes=on sortOrder:rid,rpid

 

Home Page